Menu
Not yet recruiting NCT07633782

High-Intensity Focused Electromagnetic Therapy on Patients With Patellofemoral Pain Syndrome

No phase Interventional Patellofemoral Pain Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: True High-Intensity Focused Electromagnetic Therapy, Sham High-Intensity Focused Electromagnetic Therapy, Traditional Physiotherapy.
Who it may be relevant to
Registry conditions: Patellofemoral Pain Syndrome. Basic parameters: 18 years — 45 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effect of High-Intensity Focused Electromagnetic Therapy on Pain and Quality of Life in Patients With Patellofemoral Pain Syndrome: A Randomized Controlled Trial

Overview

Evaluate the effect of High-Intensity Focused Electromagnetic Therapy on pain, quadriceps strength, and quality of life in patients with patellofemoral pain syndrome

Detailed description

Patients diagnosed with patellofemoral pain syndrome will be recruited from outpatient physical therapy clinics. Following a comprehensive clinical screening, eligible participants will be randomly assigned into two parallel groups:

The Study Group: Will receive true High-Intensity Focused Electromagnetic Therapy sessions plus a traditional physiotherapy program for 8 weeks.

The Control Group: Will receive sham High-Intensity Focused Electromagnetic Therapy sessions plus the same traditional physiotherapy program for 8 weeks.

Interventions

  • Device True High-Intensity Focused Electromagnetic Therapy
    20-30 minute sessions, 2-3 times per week for 8 weeks at a clinically effective, tolerable intensity level designed to elicit supramaximal contractions for the quadriceps muscle.
  • Device Sham High-Intensity Focused Electromagnetic Therapy
    The device protocol, application time, and acoustic feedback will the same as the experimental arm, but with the device in the off state and no muscular contractions in the quadriceps muscle .
  • Other Traditional Physiotherapy
    Standard rehabilitation program including patellar mobilization with quadriceps and hip abductor strengthening.

Primary outcome measures

  • Pain level [Time frame: Baseline and after 8 weeks]
Secondary outcome measures (2)
  • Quadriceps muscle strength [Time frame: Baseline and after 8 weeks]
  • Health-related quality of life [Time frame: Baseline and after 8 weeks]

Eligibility criteria

Inclusion criteria

  • Clinical diagnosis of patellofemoral pain syndrome (anterior or peripatellar knee pain aggravated by at least two activities such as stair climbing, prolonged sitting, squatting, or running).
  • Symptoms persisting for at least 3 months.

Exclusion criteria

  • History of previous knee surgery or trauma (e.g., ligamentous laxity, meniscal tear, or patellar fracture).
  • Concomitant knee pathology (e.g., tibiofemoral osteoarthritis, patellar tendinopathy, or plica syndrome).
  • Presence of metallic implants, pacemakers, or electrical medical devices in the body .
  • Recent corticosteroid or hyaluronic acid injection into the affected knee within the last 3 months.
  • Pregnancy.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07633782 · Electromagnetic Treatment

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗